Why the study?
There is currently no specific treatment for diabetic cardiomyopathy, though impaired mitochondrial energy metabolism is recognized as a key mediator and potential therapeutic target.
Understanding mitochondrial energy metabolism in diabetic cardiomyopathy provides mechanistic insights and highlights potential mitochondria-oriented therapeutic targets.
No specific therapy exists for diabetic cardiomyopathy; leaves open targeted intervention trials beyond glycemic and HF management.
Diabetic cardiomyopathy is defined as abnormal structure and function of the heart in the setting of diabetes, which could eventually develop heart failure and leads to the death of the patients. Although blood glucose control and medications to heart failure show beneficial effects on this disease, there is currently no specific treatment for diabetic cardiomyopathy. Over the past few decades, the pathophysiology of diabetic cardiomyopathy has been extensively studied, and an increasing number of studies pinpoint that impaired mitochondrial energy metabolism is a key mediator as well as a therapeutic target. In this review, we summarize the latest research in the field of diabetic cardiomyopathy, focusing on mitochondrial damage and adaptation, altered energy substrates, and potential therapeutic targets. A better understanding of the mitochondrial energy metabolism in diabetic cardiomyopathy may help to gain more mechanistic insights and generate more precise mitochondria-oriented therapies to treat this disease.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: